Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen

Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, Houchard A, Pavel ME (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Barcelona ES

DOI: 10.1093/annonc/mdz256.008

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

Hôpital Edouard Herriot FR France (FR) University of Warmia and Mazury in Olsztyn PL Poland (PL) Ipsen Pharma FR France (FR) University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne FR France (FR) Cliniques universitaires Saint-Luc (CHU St-Luc) BE Belgium (BE) Charité - Universitätsmedizin Berlin DE Germany (DE) Queen Elizabeth Hospital Birmingham GB United Kingdom (GB)

How to cite

APA:

Ruszniewski, P., Cwikla, J., Lombard-Bohas, C., Borbath, I., Shah, T., Pape, U.-F.,... Pavel, M.E. (2019). Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen. In ANNALS OF ONCOLOGY. Barcelona, ES: OXFORD: OXFORD UNIV PRESS.

MLA:

Ruszniewski, P., et al. "Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen." Proceedings of the 44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona OXFORD: OXFORD UNIV PRESS, 2019.

BibTeX: Download